Loading
A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia Japan K.K., now recruiting.
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients is a phase 3 interventional study registered as NCT04655092 by PharmaEssentia Japan K.K., with 67 participants planned, started 2021-01-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Polycythaemia vera (PV), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Polycythaemia vera (PV), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/